Teladoc Health (NYSE: TDOC) announced its 2020 Q4 earning results and annual results on February 24th. Although Teladoc recorded net loss of 485 million USD, total revenue was up 145% in 2020 Q4, and up 98% in twelve months (YoY).
Subscription based access fee revenue was up 149% in Q4 and up 86% in twelve months. Subscription fee accounted for as much as 78.8% of the total revenue, indicating stability of Teladoc’s management from a perspective of Cash Conversion Cycle.
Considering free cash flow margin in twelve months of -58.9% in addition ot the annual growth of total revenue, 30.4 of PSR as of February 26th indicates that the stock price may be unreasonable considering increasing interest rate of US 10 year Treasury Note.
However, since the large deficit of free cash flow is due to Livongo’s acquisition costs, Teladoc’s stock price may grow further depending on earning results in the next quarter.
- Watanabe & Brothers’ Investment is holding shares of Teladoc Health.
- This report is provided solely for informational purpose and not intended for the purpose of soliciting investment in, or as a recommendation to purchase or sell any specific products.
- Any opinions or statements expressed in this report are based on the author’s personal and subjective views, and are not the official views of the organization to which the author belongs. In addition, although we have done our best efforts in making accurate assessments on the original financial statements, we cannot guarantee any complete accuracy of this report. We do not guarantee either that any future forecasts referred to in this report will certainly be realized. Investment in listed stocks, ETFs, etc. should be carried out under the responsibility of each investor, and even if the investor who read this report suffers a loss due to investment activities, Watanabe & Brothers’ Investment is not responsible for any liability.
- This report was originally prepared in English, and translated into the other languages with plugin utilizing Google Translation API. We hereby notify that the translations are provided only for the sake of reference, and any opinions or statements in this report should be interpreted in original English. We ask any investors reading this report to refer to the original financial statements issued by the company.